Evidence map›Paper›PMID 34815256›Full record

ReviewCancer research2022

Current and Future Clinical Applications of ctDNA in Immuno-Oncology.

Julia-Christina Stadler, Yassine Belloum, Benjamin Deitert, Mark Sementsov, Isabel Heidrich, Christoffer Gebhardt, Laura Keller, Klaus Pantel

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 5 pooled it
8.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 5 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2023
    Trial
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Julia-Christina Stadler *Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Yassine Belloum *Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Benjamin DeitertDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Mark SementsovDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Isabel HeidrichDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christoffer GebhardtDepartment of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Laura Keller *Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. pantel@uke.de l.keller@uke.de.
Klaus Pantel *Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. pantel@uke.de l.keller@uke.de.
Universität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive opportunity to diagnose, characterize, and monitor the disease in individual cancer patients. ctDNA can reflect the actual tumor burden and specific genomic state of disease and thus might serve as a prognostic and predictive biomarker for immune checkpoint inhibitor (ICI) therapy. Recent studies in various cancer entities (e.g., melanoma, non-small cell lung cancer, colon cancer, and urothelial cancer) have shown that sequential ctDNA analyses allow for the identification of responders to ICI therapy, with a significant lead time to imaging. ctDNA assessment may also help distinguish pseudoprogression under ICI therapy from real progression. Developing dynamic changes in ctDNA concentrations as a potential surrogate endpoint of clinical efficacy in patients undergoing adjuvant immunotherapy is ongoing. Besides overall ctDNA burden, further ctDNA characterization can help uncover tumor-specific determinants (e.g., tumor mutational burden and microsatellite instability) of responses or resistance to immunotherapy. In future studies, standardized ctDNA assessments need to be included in interventional clinical trials across cancer entities to demonstrate the clinical utility of ctDNA as a biomarker for personalized cancer immunotherapy.

Indexed as

Biomarkers, TumorCirculating Tumor DNAHumansImmunotherapyBiomarkers, TumorCirculating Tumor DNA

Identifiers

PMID34815256
PMCPMC9397642
OpenAlexW3217207321

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.